Drug intelligence / Profile preview

lactobacillus acidophilus + bifidobacterium animalis lactis (Copenhagen University Hospital - Hvidovre)

Development stage: Unknown
Lead developer: Novonesis
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus acidophilus + Bifidobacterium animalis/lactis is a probiotic combination drug consisting of two specific bacterial strains: Lactobacillus acidophilus La-5 (LA-5) and Bifidobacterium animalis subsp. lactis BB-12 (BB-12). Formulated under the brand name Probio-Tec AB-25, this live biotherapeutic product is designed to modulate the gut microbiome and the intestinal immune environment. Its mechanism of action involves exerting anti-inflammatory and immunomodulatory effects, specifically by regulating the secretion of cytokines such as Interleukin-10 (IL-10), Transforming growth factor beta (TGF-β), Interferon gamma (IFN-γ), and Tumor necrosis factor alpha (TNF-α) by immune cells within the intestinal mucosa. The combination was primarily investigated by Hvidovre University Hospital for the maintenance of remission in patients with left-sided ulcerative colitis and proctitis. However, clinical trial results (NCT00268164) indicated that the treatment did not provide a statistically significant benefit over placebo in maintaining clinical remission over a 52-week period.

Brand names: Probio-Tec AB-25
Other names: Lactobacillus acidophilus La-5 + Bifidobacterium animalis subsp. lactis BB-12Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis

Targets

TLR2 (Toll-like Receptor 2)NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on lactobacillus acidophilus + bifidobacterium animalis lactis (Copenhagen University Hospital - Hvidovre).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus acidophilus + bifidobacterium animalis lactis (Copenhagen University Hospital - Hvidovre).

Explore the full profile